Serum activities of dipeptidyl peptidase-4 and adenosine deaminase in polycystic ovary syndrome: association with obesity

Kahraman S., Altinova A. E., ELGÜN ÜLKAR S., YALÇIN M. M., Yilmaz B. A., Ozkan C., ...Daha Fazla

GYNECOLOGICAL ENDOCRINOLOGY, cilt.35, sa.8, ss.714-718, 2019 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 8
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1080/09513590.2019.1581165
  • Dergi Adı: GYNECOLOGICAL ENDOCRINOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.714-718
  • Anahtar Kelimeler: Adenosine deaminase, dipeptidyl peptidase-4, obesity, inflammation, polycystic ovary syndrome, OXIDATIVE STRESS MARKERS, LIPID-PEROXIDATION, METABOLIC SYNDROME, CELL-ACTIVATION, GLUCOSE CONTROL, HOMEOSTASIS, DPP4, CD26
  • Ankara Üniversitesi Adresli: Evet

Özet

Dipeptidyl peptidase-4 (DPP-4) plays a role in metabolic and inflammatory diseases. Increased adenosine deaminase (ADA) has been suggested to induce insulin resistance and inflammation. We measured serum DPP-4 and ADA activities. Serum ADA activity was significantly higher in PCOS group (p=.006), whereas there was no difference in serum DPP-4 activity between the groups (p>.05). When the study subjects were divided into four groups in terms of obesity; an increasing trend in serum ADA activity between the groups was observed and ADA activity was significantly higher in overweight and obese patients with PCOS than nonobese controls (p=.016), there were no significant differences between the other groups (p>.05). A positive correlation was found between ADA and BMI in the whole group (p=.022). Multivariate regression analyses revealed that significant determinants were diastolic blood pressure, ADA, and the presence of PCOS for DPP-4 (R-2=0.344, F=9.079, p<.001); the presence of PCOS and DPP-4 for ADA (R-2=0.123, F=6.302, p=.003). We demonstrated increased serum ADA activity as well as its association with obesity in PCOS, while there was no change in serum DPP-4 activity in women with PCOS.